Antiplatelet drug is a generic term, describing agents which decrease platelet aggregation and inhibit thrombus formation. Antiplatelet drugs are most effective for arterial clots that are composed largely of platelets.
Platelets are critical in haemostasis and the development of arterial thrombi. Damaged endothelium activates platelets which respond by adhering and aggregating. Their release of thromboxane A2 and adenosine diphosphate (ADP) amplifies and propagates the process by stimulating surrounding platelets. The production of thrombin via the coagulation cascade is also accelerated, stabilising the thrombus by the conversion of fibrinogen to fibrin. Different classes of antiplatelet drugs act at different junctures in this process.
- Non-selective, irreversible inhibitor of cyclo-oxygenase which catalyses the production of thromboxane and prostaglandins.
- Antithrombotic action derives from reduction in thromboxane A2.
- Aspirin also has analgesic, anti-inflammatory and anti-oxidant properties. Some of the beneficial actions of aspirin in patients with cardiovascular disease (CVD) may be related to these as well as its antithrombotic effect, although some of these effects are only apparent at much higher doses.
- Add notes to any clinical page and create a reflective diary
- Automatically track and log every page you have viewed
- Print and export a summary to use in your appraisal
- An ADP receptor antagonist that competitively inhibits ADP from binding to platelet receptors, preventing ADP-mediated up-regulation of glycoprotein (GP) IIb/IIIa receptor, again blocking amplification of platelet aggregation.
- Direct comparison of clopidogrel may indicate that it is a slightly more effective antiplatelet drug than aspirin - for example, when compared head-to-head in the Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE) trial. But a high NNT (200) to prevent one additional event and high incremental cost (given aspirin's low cost) have meant that use of clopidogrel alone is limited to those who cannot tolerate aspirin prophylaxis. More importantly, clopidogrel is routinely used in the treatment of acute coronary system (ACS) and post-percutaneous coronary intervention (PCI) stenting in conjunction with aspirin.
- Prasugrel is a novel prodrug from the same family as clopidogrel, with more efficient platelet inhibition.
- Current National Institute for Health and Clinical Excellence (NICE) guidance recommends prasugrel in combination with aspirin in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) when:
- immediate PCI is necessary for ST segment elevation myocardial infarction (STEMI); or
- stent thrombosis occurred during treatment with clopidogrel; or
- the patient has diabetes mellitus
- The mechanism is not fully understood but it is thought to act by inhibiting adenosine uptake into platelets and reducing ADP-induced aggregation.
- Dipyridamole also has vasodilating properties that can make it unsuitable for use in those with severe coronary artery disease, unstable angina, recent myocardial infarction (MI) or left ventricular outflow obstruction.
- Abciximab was the original GP IIb/IIIa antagonist and is a monoclonal antibody with a much prolonged duration compared to newer agents, eg eptifibatide which is a non-peptide antagonist.
- These drugs inhibit the final common pathway of platelet aggregation where fibrinogen binds to GP IIb/IIIa receptor.
- All require intravenous administration under specialist supervision. Patients receiving these drugs require very close monitoring, usually on coronary care units (CCUs).
- Thromboxane A2 and ADP are just two of over 90 known platelet agonists. Blockade by aspirin and clopidogrel will not affect the platelet's ability to be stimulated by other agonists whilst use of a GP IIb/IIIa antagonist should inhibit aggregate formation whatever agonist influences the platelet.
- Neutralising antibodies to abciximab form, so it can only be used once.
- GP IIb/IIIa antagonists can cause severe bleeding, most often from the site of femoral puncture for percutaneous transluminal coronary angioplasty (PTCA). It can take over 12 hours for platelet function to be restored after stopping an infusion.
- Ticagrelor - licensed for use with aspirin in preventing atherothrombotic events in acute coronary syndrome (ACS) for 12 months, and can be used for both medical management or where further coronary intervention is planned. If it needs to be continued beyond this then the diagnosis should be confirmed by a cardiology specialist.
- Primary prevention of cardiovascular disease (CVD):
- Previously, aspirin was recommended for those without apparent CVD in whom the total CVD risk over 10 years is >20%, and for almost all diabetic patients over the age of 50 years. The evidence to support this unlicensed indication is not robust and thus current guidance is that aspirin should not be used in primary prevention (including in those with diabetes mellitus or hypertension). But note: aspirin is increasingly being used in the primary prevention of some cancers - particularly bowel cancer.
- Clopidogrel and dipyridamole are neither indicated nor licensed for primary prevention of cardiovascular (CV) events.
- Secondary prevention of CVD:
- In those with established atherosclerotic disease, low-dose aspirin (75 mg daily) is recommended indefinitely for long-term secondary prevention. Antithrombotic Trialists' Collaboration (ATTC) provided evidence that this reduces the risk of any serious vascular event by 25% and vascular mortality by a sixth.
- Modified-release dipyridamole 200 mg bd plus low-dose aspirin (50 mg or 75 mg daily) is recommended for secondary prevention following an ischaemic stroke or a transient ischaemic attack (TIA) for a period of two years from the most recent event, based on the second European Stroke Prevention (EPS-2) trial. EPS-2's findings have been replicated by the more recent European/Australasian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT) study. Evidence of long-term benefit was not established by EPS-2, so NICE guidance limited treatment duration to two years with preventative treatment reverting to standard treatment (eg low-dose aspirin) but it should probably continue with no time limit.
- Where aspirin is contra-indicated or genuinely not tolerated (ie proven hypersensitivity or history of severe low-dose aspirin-induced dyspepsia), clopidogrel 75 mg daily is a suitable alternative to aspirin (or aspirin plus dipyridamole post-stroke).
- There may be a role for triple antiplatelet therapy in the secondary prevention of CVD but this is as yet unlicensed.
- Acute ischaemic events:
- A single dose of aspirin 300 mg and clopidogrel 300 mg (600 mg - unlicensed in some centres prior to urgent percutaneous coronary intervention (PCI)) should be given as soon as possible after an ischaemic event (both non-ST segment elevation myocardial infarction (NSTEMI) and STEMI), preferably dispersed in water or chewed.
- Clopidogrel 75 mg daily is licensed for the treatment of acute coronary syndrome (ACS) ± ST elevation, in combination with aspirin (usually following loading doses).
- Post-PCI clopidogrel 75 mg should continue for one month if a bare metal stent is inserted and 12 months if a drug-eluting stent is inserted. Thereafter, treatment should revert to low-dose aspirin alone.
- Eptifibatide and tirofiban are licensed for use with heparin and aspirin to prevent early MI in patients with unstable angina or NSTEMI where early percutaneous transluminal coronary angioplasty (PTCA) is desirable but delay is likely.
- PCI: abciximab is licensed as an adjunct to heparin and aspirin for the prevention of ischaemic complications in high-risk patients undergoing PCI, and NICE suggests that GP IIb/IIIa inhibitors be used as adjuncts where the procedure is complex or is delayed and in patients with diabetes.
- Eptifibatide: this is also used in NSTEMI where the last episode of chest pain was within 24 hours.
- Rarely, GP IIb/IIIa inhibitors are used in complex patients with unstable angina or an acute coronary syndrome (ACS) which is not responding to conventional therapy (under specialist supervision).
- Acute ischaemic stroke - thrombolyse if appropriate and follow with aspirin 300 mg once daily for 14 days. If not able to be thrombolysed then aspirin alone should be given. Aspirin caused an excess of about two intracranial and four extracranial haemorrhages per 1,000 people treated, but these small risks were more than offset by the reductions in death and disability from other causes.
- Long-term management of both TIA or ischaemic stroke - dipyridamole 200 mg bd with aspirin 75 mg once daily.
- If aspirin cannot be used then modified-release dipyridamole is the choice.
- If there are reasons why both aspirin and dipyridamole cannot be used - clopidogrel 75 mg would be the alternative, although this is currently unlicensed.
- Atrial fibrillation (AF) carries a high risk of stroke and other thromboembolic events. Warfarin is more efficacious than aspirin at preventing stroke (particularly in those at highest risk) but carries a greater risk of major haemorrhage:
- Overall baseline risk is 51 strokes per 1,000 patient years.
- Warfarin will prevent 28 strokes at the cost of 11 major bleeds.
- Aspirin will prevent 16 strokes at the cost of 6 major bleeds.
Individual decisions to take aspirin or warfarin for thromboprophylaxis with AF remain difficult. The CHA2DS2-VASc score is one method of assessing stroke risk (it has superseded the CHADS2 score):
CHA2DS2-VAScConditionPointsC Congestive heart failure (or left ventricular (LV) dysfunction). 1H Hypertension. 1A2 Age ≥75 years. 2D Diabetes mellitus. 1S2 Prior stroke, TIA or thromboembolic disease. 2V Vascular disease - eg presence of peripheral vascular disease, myocardial infarction, aortic atherosclerosis. 1A Age 65-74 years. 1Sc Sex category (ie female). 1
- Score 0 = low risk; no treatment or treat with aspirin.
- Score 1 = moderate risk; aspirin daily or warfarin based on the patient's preference. Warfarin is probably preferred if there are no contra-indications.
- Score 2 or more = high risk; treat with warfarin maintaining an INR 2-3.
Decisions for those with moderate risk are obviously hardest - lack of clear-cut evidence means that the decision to use warfarin or aspirin in this group should be individual, based on risk of bleeding and personal preference. Bleeding risk with warfarin is higher where:
- Age is over 75 years.
- There is concurrent treatment with non-steroidal anti-inflammatory drugs (NSAIDs).
- There is a past history of bleeding.
- Uncontrolled hypertension.
- Start antithrombotic treatment where indicated as soon as possible following diagnosis of AF.
- Treatment decisions should be made in the same way for paroxysmal AF.
- Recent research in AF suggests that patients who are unsuitable for anticoagulants may get additional benefit if aspirin and clopidogrel are combined rather than using aspirin alone.
- Pre-eclampsia is associated with excessive production of thromboxane so antiplatelet agents have been proposed as possible therapy to prevent or delay the development of pre-eclampsia. A Cochrane review found that antiplatelet agents (primarily low-dose aspirin) did indeed have small-to-moderate benefits in the prevention of pre-eclampsia but research evidence is still required as to which women are most likely to benefit, when to start treatment, suitable dose, etc. Antiplatelet drugs are not licensed for this use.
See individual drug profiles, but some general or important points:
- All antiplatelet drugs can cause bleeding. Avoid in patients who are at a high risk of bleeding or where the consequences of bleeding would be severe - for example, active peptic ulcer disease, uncontrolled hypertension.
- Hypersensitivity and allergy. NICE guidance suggests that true hypersensitivity to aspirin (characterised by rash, urticaria and angio-oedema) is rare.
- Aspirin can cause bronchospasm and worsen pre-existing asthma. A systematic review estimated the prevalence of aspirin-exacerbated asthma in adults with pre-existing asthma as 21 % (from oral provocation testing). From this, it suggests that approximately 80% of asthmatics can take aspirin safely but caution should be exercised. Always check about previous experiences with aspirin and other NSAIDs and warn to stop aspirin if their asthma deteriorates. High-risk features for developing aspirin-induced asthma include severe asthma, nasal polyps, urticaria and rhinitis.
- Hypertension should be controlled (blood pressure (BP) <150/90 mm Hg) before commencing treatment.
See individual drugs. All antiplatelet drugs can cause gastrointestinal (GI) disturbance and bleeding - dipyridamole is the least risky (but is rarely used alone) to the high risk associated with the GP IIb/IIIa antagonists.
Check the individual drug. Be wary of co-prescribing with other drugs that increase risk of bleeding (ie warfarin and heparin, other antiplatelet drugs, corticosteroids, iloprost). Adding clopidogrel to aspirin increases the antiplatelet effect but also increases the risk of bleeding so is only justified where the risk is outweighed by the potential benefit.
Screening, risk assessment and communication
- Appropriate identification of patients remains a challenge:
- Many of the guidelines advocate case-finding of those at high CV risk by screening.
- Asymptomatic adults aged 40 years and over (younger where there is a family history of premature cardiovascular disease (CVD)) should receive opportunistic comprehensive CV risk assessment using Joint British Societies' (JBS) risk prediction charts.
- The Scottish Intercollegiate Guidelines Network (SIGN) suggests five-yearly reviews of the same groups.
- By the age of 50, 90% of the UK population are at sufficient CV risk to require treatment according to current guidelines, and normal symptom-free individuals become 'patients'.
- Screening makes sense from a population perspective where lives are undoubtedly saved but, on an individual basis, a small reduction in CV risk will lead to very little absolute benefit with all the disadvantages of medicalising lives.
- Communicating balances of risk and benefit to individuals is demanding. Even where figures derived from clinical trials can be applied straightforwardly to a patient's case, it is impossible to predict whether a particular individual will benefit, be harmed or receive no effect either way from a particular treatment. Sharing this uncertainty is very difficult.
- High-risk individuals for primary and secondary prevention should be identifiable from disease registers. CVD prevention (including the use of antiplatelet drugs) within a practice can be audited against JBS' standards.
- The new General Medical Services (nGMS) contract uses antiplatelet therapy as a quality indicator in three domains (CHD 9, STROKE 8 and AF 3) so it is particularly important to consider treatment (where appropriate) and record contra-indications or side-effects to meet targets.
- Routine monitoring of antiplatelet treatment for primary and secondary prevention is not usually required.
- It should be remembered that antiplatelet therapy reduces but does not eliminate the risk of CV events. Where patients suffer a CV event whilst on antiplatelet medication, it should not be assumed that they are 'resistant' to the drug's antiplatelet effect or that a switch to another agent would offer any greater protection. True resistance to the antiplatelet action of aspirin or clopidogrel may occur in a small proportion of patients but there are no reliable tests available currently to confirm this. Seek expert advice.
- What dose of aspirin? Antithrombotic Trialists' Collaboration (ATTC) provided good evidence that lower doses of aspirin (75-150 mg) were no less effective than higher ones, with a reduced rate of bleeding complications. Common practice is to prescribe 75 mg daily for primary and secondary prevention of CVD, although a lot of cardiologists seem to use 150 mg daily.
- GI side-effects are common with aspirin:
- Advise patients to report any abdominal pain, melaena or rectal bleeding urgently.
- There is no evidence that enteric coating or dispersible formulations of aspirin lessen the risk.
- Ensure that it is taken with food.
- Co-prescription of symptomatic or preventative medication - for example, maintenance dose protein pump inhibitor (PPI) - should be used prior to switching to clopidogrel where similar side-effects may occur.
- Good communication between primary and secondary care is important. For example:
- Ensuring that where aspirin is given for acute coronary syndrome (ACS), it is documented and passed on to paramedics/admitting team.
- Discharge plans from CCU/stroke unit should make it clear, to primary care and to the patient, what the long-term plan for medication is and, in particular, when to stop clopidogrel or dipyridamole.
- Ensure mechanisms for stopping clopidogrel and dipyridamole at the correct times through regular medication reviews.
- Auditing prescribing of clopidogrel and dipyridamole will help to ensure that their use falls within the limited indications.
Elective surgery - stopping antiplatelet drugs
- The usual advice is that aspirin should be stopped 5-9 days prior to surgery and clopidogrel stopped seven days before to reduce the risk of bleeding complications.
- However, it has been suggested that stopping aspirin leads to a rapid loss of protection and even rebound increased risk of ischaemic event.
- There also is the risk that the drug may not be restarted.
- This may make us question the wisdom of stopping antiplatelet agents, in high-risk individuals, for minor surgical procedures, such as skin or cataract surgery.
- In general, aspirin should be stopped where the risk of postoperative bleeding is high (eg during major surgery) or where the consequences of even minor bleeding are significant (eg retinal and intracranial surgery).
- If concerned, discuss with the surgeon or dentist.
Further reading & references
- British Heart Foundation
- Small daily aspirin dose 'cuts cancer risk'; Small daily aspirin dose 'cuts cancer risk', BBC news report November 2010; Includes video interview with main author of Lancet study
- Collection of evidence-based essays on aspirin, including analgesic effect, cancer prevention, harm assessments, CVD prevention and other aspects (e.g. pre-eclampsia, DVT prophylaxis for travel), Bandolier
- Primary Care Cardiovascular Society
- Knight CJ; Antiplatelet treatment in stable coronary artery disease.; Heart. 2003 Oct;89(10):1273-8.
- Summary of Product Characteristics (SPC) - Plavix®; Summary of Product Characteristics (SPC) - Plavix® (clopidogrel hydrogen sulphate), sanofi-aventis, electronic Medicines Compendium. Last revised April 2010
- No authors listed; A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.; Lancet. 1996 Nov 16;348(9038):1329-39.
- Vascular disease - clopidogrel and dipyridamole, NICE Technology Appraisal Guideline (December 2010)
- Summary of Product Characteristics (SPC) - Persantin®; Summary of Product Characteristics (SPC) - Persantin® 100 mg tablets (dipyridamole), Boehringer Ingelheim Ltd, electronic Medicines Compendium. Last revised May 2007
- Saino T, Misaki T, Matsuura M, et al; Dipyridamole inhibits intracellular calcium transients in isolated rat arteriole Arch Histol Cytol. 2008 Dec;71(4):235-47.
- Summary of Product Characteristics (SPC) - Reopro®; Summary of Product Characteristics (SPC) - Reopro® 2 mg/ml solution for injection or infusion (abciximab), Eli Lilly and Co Ltd, electronic Medicines Compendium. Last revised March 2011
- Summary of Product Characteristics (SPC) - Integrilin®; Summary of Product Characteristics (SPC) - Integrilin® 2 mg solution for injection, 0.75 mg solution for infusion, GlaxoSmithKline UK, electronic Medicines Compendium. Last revised July 2011
- Summary of Product Characteristics (SPC) - Aggrastat®; Summary of Product Characteristics (SPC) - Aggrastat® solution for infusion and concentrate for solution for infusion, Iroko Cardio GmbH, electronic Medicines Compendium. Last revised September 2010
- Acute coronary syndromes - ticagrelor, NICE Technology Appraisal Guideline (October 2011)
- Summary of Product Characteristics (SPC) - Ticagrelor; film coated tablets, AstraZeneka UK Limited, electronic Medicines Compendium. December 2010
- Barnett H, Burrill P, Iheanacho I; Don't use aspirin for primary prevention of cardiovascular disease. BMJ. 2010 Apr 21;340:c1805. doi: 10.1136/bmj.c1805.
- Rothwell PM, Fowkes FG, Belch JF, et al; Effect of daily aspirin on long-term risk of death due to cancer: analysis of Lancet. 2011 Jan 1;377(9759):31-41. Epub 2010 Dec 6.
- No authors listed; Drugs to prevent vascular events after stroke.; Drug Ther Bull. 2005 Jul;43(7):53-6.
- No authors listed; Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.; BMJ. 2002 Jan 12;324(7329):71-86.
- Diener HC, Cunha L, Forbes C, et al; European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke.; J Neurol Sci. 1996 Nov;143(1-2):1-13.
- Halkes PH, van Gijn J, Kappelle LJ, et al; Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet. 2006 May 20;367(9523):1665-73.
- Sprigg N, Gray LJ, England T, et al; A randomised controlled trial of triple antiplatelet therapy (aspirin, clopidogrel and dipyridamole) in the secondary prevention of stroke: safety, tolerability and feasibility. PLoS One. 2008 Aug 6;3(8):e2852.
- Unstable angina and NSTEMI, NICE Clinical Guideline (March 2010)
- Sabatine MS, Cannon CP, Gibson CM, et al; Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005 Mar 24;352(12):1179-89. Epub 2005 Mar 9.
- Chen ZM, Jiang LX, Chen YP, et al; Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005 Nov 5;366(9497):1607-21.
- Squizzato A, Keller T, Romualdi E, et al; Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular Cochrane Database Syst Rev. 2011 Jan 19;(1):CD005158.
- Antiplatelet Treatment, Prodigy (July 2009)
- Acute coronary syndromes - glycoprotein IIb/IIIa inhibitors, NICE Technology Appraisal (2002)
- Gubitz G, Sandercock P, Counsell C; Anticoagulants for acute ischaemic stroke.; Cochrane Database Syst Rev. 2004;(3):CD000024.
- Camm AJ, Kirchhof P, Lip GY, et al; Guidelines for the management of atrial fibrillation: the Task Force for the Eur Heart J. 2010 Oct;31(19):2369-429. Epub 2010 Aug 29.
- Connolly SJ, Pogue J, Hart RG, et al; Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009 May 14;360(20):2066-78. Epub 2009 Mar 31.
- Duley L, Henderson-Smart Dj, Meher S, et al; Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev. 2007 Apr 18;(2):CD004659.
- Summary of Product Characteristics (SPC) - Aspirin Caplets®; Summary of Product Characteristics (SPC) - Aspirin Caplets®, 300 mg, Boots Company PLC, electronic Medicines Compendium. Last revised November 2004
- Jenkins C, Costello J, Hodge L; Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice.; BMJ. 2004 Feb 21;328(7437):434.
- No authors listed; JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart. 2005 Dec;91 Suppl 5:v1-52
- Risk estimation and the prevention of cardiovascular disease, Scottish Intercollegiate Guidelines Network - SIGN (2007)
- Westin S, Heath I; Thresholds for normal blood pressure and serum cholesterol. BMJ. 2005 Jun 25;330(7506):1461-2.
- Revisions to the GMS contract 2006/7, NHS Employers
- Prescribing antiplatelet drugs in primary care, MeReC Bulletin, Vol 15, No 6, 2005
- Cahill RA, McGreal GT, Crowe BH, et al; Duration of increased bleeding tendency after cessation of aspirin therapy.; J Am Coll Surg. 2005 Apr;200(4):564-73; quiz A59-61.
|Original Author: Dr Chloe Borton||Current Version: Dr Gurvinder Rull||Peer Reviewer: Dr Adrian Bonsall|
|Last Checked: 19/07/2012||Document ID: 268 Version: 7||© EMIS|
Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. EMIS has used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our conditions.